Overlevelsesgevinsten ved Vidaza var konsekvent, uanset hvilken CCR- behandlingsoption (BSC alene, lavdosis cytarabin plus BSC eller standard induktionskemoterapi plus BSC), der blev anvendt i kontrolgruppen.
The survival benefits of Vidaza were consistent regardless of the CCR treatment option (BSC alone, low-dose cytarabine plus BSC or standard induction chemotherapy plus BSC) utilised in the control arm.